Key Takeaways
- Cenexi reaches breakeven, the quarter's headline event: After several quarters of negative EBITDA, Cenexi turned EBITDA breakeven in Q1 FY26, validating the strategic shift toward higher-value formats.
- Base business margins surge on raw material tailwinds: Base business EBITDA margin jumped to 35% from 29% YoY, driven by favorable raw material costs for several key products and cost control, pushing consolidated EBITDA margin to 24%.
- U.S. growth story intact beneath enoxaparin noise: U.S. revenue declined ~2% (Gland portfolio -5%) solely due to enoxaparin timing, with large dosage SKUs not supplied every quarter; excluding enoxaparin, U.S. grew ~11%.
- GLP-1 capacity build is a FY'29 story, not FY'27: Management is expanding cartridge capacity from 4 crore to 14 crore units, but stated "majority of the capacities will start filling up from '29 and '30," with FY'27 utilization minimal as most markets open later.
- What to watch next quarter: Whether Cenexi's Q2 seasonal dip stays contained and the promised Q3 ramp-up materializes, the pace of U.S. complex injectable approvals, and any tariff clarity for generics.
Cenexi Turnaround
- Breakeven achieved: Cenexi delivered EUR 0.9 million EBITDA in Q1 FY26 after several quarters of losses, with revenue of EUR 48 million and gross margin improving to 80% from 78%.
- Strategic shift working: The turnaround was driven by a deliberate move from low-value, high-volume products to higher-value offerings including prefilled syringes, lyophilised vials, and ophthalmic gels.
- All sites contributed: Braine-l'Alleud and Osny continued their positive trend, while Fontenay and Herouville, the previously underperforming sites, showed recovery driven by increased volume, reduced downtime, and productivity actions. Fontenay benefited from a new line added in March that helped catch up on back orders and increase capacity.
- HSC product launches: The HSC site launched two products: Encepur and Fucithalmic gel vaccine products.
- Order book holding: The order book remains at EUR 85-90 million despite producing more to clear backlog, indicating sustained demand.
- Capacity constraints at two sites: Osny and Fontenay are at peak utilization, with the strategy shifting to price increases and higher-value formats; Herouville has ample runway with tech transfers, while HSC and Braine-l'Alleud have available capacity.
- Q2 seasonal dip expected: Management flagged a to-be-expected low Q2 FY26 due to the summer shutdown, with EBITDA turning positive again from October onward.
Srinivas Sadu: "Fontenay site, I think, we were struggling to deliver the demand and the line which we have added in March that kind of helped us to catch up with some of the back orders and also increase the capacity. So that was added in Fontenay and brought into green."
Base Business Margin Expansion
- Raw material tailwind: Base business gross margin improved to 59% from 53% YoY, and EBITDA margin to 35% from 29% YoY, driven by favorable raw material costs for several key products and cost control initiatives.
- Consolidated margin lift: Consolidated gross margin improved to 65% from 60% YoY, largely due to the higher contribution from favorable raw material costs at the base business.
- Consolidated EBITDA: EBITDA grew 39% YoY to ₹367.8 crore, with margin expanding from 19% to 24%, driven by EBITDA expansion in the base business and Cenexi turning breakeven.
- Combined margin run-rate: Management indicated the combined Gland plus Cenexi consolidated EBITDA margin is running at approximately 24%-25% for the current quarter.
- R&D expense timing: R&D expense declined to ₹46 crore from ₹48.9 crore in Q1 FY25, largely due to timing of expenses, with all R&D programs remaining on track.
- Cash conversion improvement: The cash conversion cycle improved to 161 days from 172 days at the end of FY25, due to better receivable and payable management.
U.S. Business & Launch Momentum
- Enoxaparin masks underlying growth: U.S. revenue declined ~2% (Gland portfolio -5%) solely due to enoxaparin timing, as large dosage SKUs are not supplied every quarter; annual enoxaparin volume and revenue remain intact. Excluding enoxaparin, U.S. grew ~11%.
- Nine new molecule launches: Q1 saw nine new molecule launches including Epinephrine, Acetaminophen Bags, and three new strengths of Vancomycin, with management confident of sustaining this nine-product-per-quarter launch momentum.
- Mid-teen growth on track: Management confirmed they are on track to achieve mid-teen growth for the full year, having achieved budget in Q1, with Dalbavancin and CMS project launches in the last two quarters providing a big jump.
- Complex injectables pipeline: Three more complex injectable products are in line for approval, with more products being added to the pipeline.
- RTU infusion bag progress: One RTU infusion bag was filed in Q1; total 20 filed in the U.S., 14 approved, with 10 more under development.
- Tariff uncertainty lingers: No tariffs have been imposed on pharma yet, but management noted "everybody is now keeping fingers crossed," with market expectations that generics may receive exemption while branded products face large tariffs.
Srinivas Sadu: "everybody is now keeping fingers crossed when and how much they will charge because the market says for generic there may be exemption, but mostly on the branded side they may put/impose large tariffs."
GLP-1 Capacity Build & Commercialization Timeline
- Massive capacity expansion: Cartridge capacity is expanding from 4 crore units to over 14 crore units, with new lines integrated with pen assembly; Factory Acceptance Test scheduled by September 2025, installation in November.
- Commercialization is back-end loaded: Management explicitly stated "majority of the capacities will start filling up from '29 and '30," with FY'27 utilization minimal as most markets open later. New 10 crore capacity will be ready for commercialization by March/April.
- FY'27 volume guidance modest: Management guided "around 2 crore in the first year" (FY'27) for pen/cartridge capacity utilization, a small fraction of the 14 crore total capacity.
- Four-pronged customer strategy: The company is talking to four types of customers: Indian customers for global markets, global customers for India, Indian customers for India, and global players for global markets. Capacities are being "lapped up," with exact capacity sold expected to be known by end of Q4 FY'26.
- Current utilization minimal: Currently, very limited commercial utilization exists, only for Liraglutide; most capacity is used for development and exhibit batches for other CDMO contracts, with commercial launches of Ozempic/Wegovy needed for higher utilization.
- Additional lines ready: Other lines will be ready by Q1 of next year to handle demand.
Shyamakant Giri: "We are talking to four types of customers - Indian customers for global market, Global customers for India market, Indian customer for Indian market. And finally, we are talking to also some more players for global markets."
Liraglutide & Peptide Launches
- Four markets now live: Liraglutide launched in the U.K. and Australia this quarter, adding to previous launches in South Africa and Saudi Arabia, bringing the total to four markets.
- More markets in pipeline: Mexico and a few other markets are in the pipeline to be launched this year.
- Revenue details withheld: Management declined to disclose liraglutide revenue by geography or the number of additional markets planned for the remaining quarters of FY'26, citing partner confidentiality.
- Semaglutide cannibalization addressed: When asked if liraglutide would cannibalize future semaglutide business from a manufacturing capacity standpoint, management stated enough capacity exists, with the products serving separate markets.
- Pricing not disclosed: Management declined to comment on semaglutide pricing or revenue potential, stating "we're not dependent on end pricing."
Other Markets & Partnerships
- Other regulated markets surge: 34% YoY growth led by portfolio maximization initiatives across partners, now representing 27% of total revenue.
- Rest of World recovery: RoW arrested de-growth with 24% QoQ growth and 5% YoY growth, driven by portfolio optimization, country classification (Class 1/2/3), reactivation of old registrations, and high-cadence partner reviews.
- Europe growth drivers: YoY growth in Europe came mostly from the CMS product launch and Liraglutide launch in the U.K.
- CMS project progressing: The on-market product transfer from a European site to Gland is underway; a lyophilized product has already launched and been approved; dry powder dossiers are being filed, with approval expected Q1 next year. The CMS dry powder launch is described as a "big-ticket item" for the CDMO business.
- Dr. Reddy's biosimilar collaboration: Started July 1st with the team in place; revenue is expected from this quarter onward. Other biosimilar projects remain in RFP and commercial discussion stages, with tech transfer activities expected next year.
- India market small but targeted: India revenue was ₹59.4 crore (4% of revenue), with management actively exploring inorganic opportunities to achieve significant growth.
- Generic Vyzulta launch: Targeted for FY'29, depending on settlement and patent outcomes.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi EBITDA positive | Turn EBITDA positive after seasonal Q2 dip | From October (Q3 FY'26) onward |
| Cenexi margin trajectory | Ramp to low teens or high single digits EBITDA | No specific date; "ramp it up slowly" |
| U.S. mid-teen growth | Achieve mid-teen growth for full year | FY'26 |
| Pen/cartridge capacity utilization | ~2 crore units utilized | FY'27 (first year) |
| GLP-1 capacity commercialization | New 10 crore capacity ready; majority of utilization | Ready by Mar/Apr '26; majority filling from FY'29-FY'30 |
| CMS dry powder launch | Dossiers submitted next quarter; products launch | Beginning of next year (Europe and other markets) |
| New prefilled syringe line (Herouville) | Operational | Beginning of calendar year 2026 |
| New lyophilizers (Braine-l'Alleud) | Qualifications concluded | End of calendar year 2025 |
| Generic Vyzulta launch | Subject to settlement and patent | FY'29 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated revenue | ₹1,505.6 crore, +7% YoY |
| Consolidated EBITDA | ₹367.8 crore, +39% YoY |
| Consolidated EBITDA margin | 24%, up from 19% in Q1 FY25 |
| Consolidated gross margin | 65%, up from 60% in Q1 FY25 |
| Net profit | ₹215.5 crore, +50% YoY |
| PAT margin | 14%, up from 10% in Q1 FY25 |
| Base business revenue growth (ex-Cenexi) | 3% YoY |
| Base business EBITDA margin (ex-Cenexi) | 35%, up from 29% in Q1 FY25 |
| Base business gross margin (ex-Cenexi) | 59%, up from 53% in Q1 FY25 |
| U.S. revenue | ₹744.3 crore, 49% of total revenue |
| Other regulated markets revenue growth | +34% YoY, 27% of total revenue |
| Rest of World revenue | ₹297.8 crore, +5% YoY and +24% QoQ, 20% of total revenue |
| India revenue | ₹59.4 crore, 4% of total revenue |
| Cenexi revenue | EUR 48 million |
| Cenexi EBITDA | EUR 0.9 million, breakeven achieved |
| Cenexi gross margin | 80%, up from 78% in Q1 FY25 |
| R&D expenditure | ₹46 crore, 4.4% of base business revenue |
| U.S. new product launches | 9 new molecules launched |
| ANDA filings and approvals | 1 ANDA filed, 9 approved |
| RTU bag portfolio filed in U.S. | 20 products filed, 14 approved |
| Co-development portfolio | 15 products, including 7 505(b)(2) and 8 ANDAs |
| Cash and equivalents (group level) | ₹3,013.9 crore as of June 30, 2025, including ₹396 crore non-callable deposit |
| Cash flow from operations | ₹262 crore |
| Cash conversion cycle | 161 days, improved from 172 days at FY25 end |
| Total capex | ₹78.6 crore |
| Effective tax rate (standalone) | 25.7% |
| Pen and cartridge capacity | 4 crore units operational, expanding to over 14 crore units |
| Cenexi order book | EUR 85–90 million |